Summary:
Hematopoietic stem cell transplantation (HSCT) is the only curative option for patients with hemoglobinopathies. However, fewer than 30% of individuals will have an HLA-identical sibling. Improvement in outcomes after HSCT using unrelated donors (URD), and the development of novel nontoxic preparative regimens may make URD HSCT an option for hemoglobinopathy patients who do not have an HLA-identical sibling donor. The National Marrow Donor ProgramĀ® (NMDP) maintains a Registry of 4 million volunteer donors, and facilitates URD HSCT for patients with life-threatening blood diseases. In light of the increased representation of minorities in the NMDP registry, donor searches were run in April 2001 for a cohort of 272 thalassemia patients and 77 sickle cell disease (SCD) patients for whom searches had been submitted between 1989 and 2001 in order to determine the current likelihood of finding a potential donor of hematopoietic stem cells for hemoglobinopathy patients. About 59.7% SCD patients 80.2% thalassemia patients will find at least one potential 6/6 HLA matched donor or umbilical cord blood (UCB) unit. All patients will find at least one donor or UCB that is a potential 5/6 HLA match. In conclusion the majority of hemoglobinopathy patients will find at least one potential HLA matched unrelated bone marrow donor or UCB.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Walters MC, Storb R, Patience M et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood 2000; 95: 1918ā1924.
Lucarelli G, Galimberti M, Giardini C et al. Bone marrow transplantation in thalassemia. The experience of Pesaro. Ann NY Acad Sci 1998; 850: 270ā275.
Walters MC, Patience M, Leisenring W et al. Barriers to bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant 1996; 2: 100ā104.
Gaziev D, Galimberti M, Lucarelli G et al. Bone marrow transplantation from alternative donors for thalassemia: HLA-phenotypically identical relative and HLA-nonidentical sibling or parent transplants. Bone Marrow Transplant 2000; 25: 815ā821.
La Nasa G, Giardini C, Argiolu F et al. Unrelated donor bone marrow transplantation for thalassemia: the effect of extended haplotypes. Blood 2002; 99: 4350ā4356.
Crespo Chozas D, Maldonado Regalado MS, Munoz Villa A . Unrelated donor bone marrow transplantation in a girl with thalassemia major. Med Clin (Barc) 2000; 114: 598ā599.
Contu L, La Nasa G, Arras M et al. Successful unrelated bone marrow transplantation in beta-thalassaemia. Bone Marrow Transplant 1994; 13: 329ā331.
Cheng CN, Lu CC, Sun HF et al. Successful matched-unrelated bone marrow transplantation in a patient with Beta-thalassemia major. J Pediatr Hematol Oncol 2002; 24: 579ā581.
Golden F . The sickle-cell kid. An experimental transplant succeeds, giving a brave little boy the best Christmas present he can imagine. Time 1999; 154: 92.
Sullivan KM, Anasetti C, Horowitz M et al. Unrelated and HLA-nonidentical related donor marrow transplantation for thalassemia and leukemia. A combined report from the Seattle Marrow Transplant Team and the International Bone Marrow Transplant Registry. Ann NY Acad Sci 1998; 850: 312ā324.
Maiers M, Flesch S . Unrelated Donor Hematopoetic Stem Cell Transplantation for Hemoglobinopathies Facilitated by NMDP. National Marrow Donor Program: Minneapolis; 2002.
Krishnamurti L, Blazar BR, Wagner JE . Bone marrow transplantation without myeloablation for sickle cell disease. N Engl J Med 2001; 344: 68.
Schleuning M, Stoetzer O, Waterhouse C et al. Hematopoietic stem cell transplantation after reduced-intensity conditioning as treatment of sickle cell disease. Exp Hematol 2002; 30: 7ā10.
Chakraverty R, Peggs K, Chopra R et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002; 99: 1071ā1078.
Anasetti C, Petersdorf EW, Martin PJ et al. Improving availability and safety of unrelated donor transplants. Curr Opin Oncol 2000; 12: 121ā126.
Gutoski M . Study verifies lack of ethnic diversity in bone marrow donors. Oncol Nurs Forum. 1995; 22: 717.
Freytes CO, Beatty PG . Representation of Hispanics in the National Marrow Donor Program. Bone Marrow Transplant 1996; 17: 323ā327.
Yancey AK, Coppo P, Kawanishi Y . Progress in availability of donors of color: the National Marrow Donor Program. Transplant Proc 1997; 29: 3760ā3765.
Antin JH, Childs R, Filipovich AH et al. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 tandem meetings. Biol Blood Marrow Transplant 2001; 7: 473ā485.
Davies SM, DeFor TE, McGlave PB et al. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. Am J Med 2001; 110: 339ā346.
Mentzer WC . Bone marrow transplantation for hemoglobinopathies. Curr Opin Hematol 2000; 7: 95ā100.
Confer DL . The National Marrow Donor Program. Meeting the needs of the medically underserved. Cancer 2001; 91: 274ā278.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Krishnamurti, L., Abel, S., Maiers, M. et al. Availability of unrelated donors for hematopoietic stem cell transplantation for hemoglobinopathies. Bone Marrow Transplant 31, 547ā550 (2003). https://doi.org/10.1038/sj.bmt.1703887
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703887
Keywords
This article is cited by
-
Decision-making about gene therapy in transfusion dependent thalassemia
BMC Pediatrics (2022)
-
Has stem cell transplantation come of age in the treatment of sickle cell disease?
Bone Marrow Transplantation (2007)
-
Marrow graft rejection by repeated transfusions of allogeneic donor spleen cells
Bone Marrow Transplantation (2007)